Skip to main content

Table 1 Patient’s laboratory results at different time points

From: A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report

Time

Haemoglobin level

(reference range 11.5–14.5 g/dL)

Platelet count

(reference range 150–400 × 109/L)

C3 level

(reference range 0.80–1.60 g/L)

Protein excretion in first-morning urine dipstick

(reference range < 30 mg/dL)

At time of diagnosis and eculizumab initiation

5.9

23

0.55

> 400

1 month after diagnosis

9

169

0.91

100

6 months on eculizumab every 2 weeks

11.8

543

NA

100

1 month after increasing the eculizumab interval to every 3 weeks

12.2

494

0.78

300

4 months after increasing the eculizumab interval to every 3 weeks

11.1

462

NA

300

1 month after resuming eculizumab every 2 weeks

12.2

491

NA

100

4 months after resuming eculizumab every 2 weeks

11

641

NA

100